Bill > A05392

This bill expands the definition of epinephrine devices to include nasal spray and other FDA-approved devices for emergency treatment of anaphylaxis, beyond the previous narrow definition of auto-injectors. The legislation modifies multiple sections of New York's public health, education, and insurance laws to reflect this broader definition. Specifically, the bill allows various entities like schools, camps, sports facilities, and public assembly venues to purchase, possess, and use these expanded epinephrine devices. It requires that individuals using these devices receive proper training in recognizing allergic symptoms and administering the medication. The bill also mandates that health insurance policies cover these devices with an annual out-of-pocket cost cap of $100. Additionally, the legislation maintains existing protections for organizations and individuals who use epinephrine devices in good faith during emergency situations, ensuring they are not liable for damages when voluntarily rendering first aid. The changes aim to increase accessibility and preparedness for treating severe allergic reactions across various settings in New York State.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A5392